Core Insights - IGI Therapeutics SA and AbbVie Inc. have entered into an exclusive licensing agreement for IGI's investigational asset ISB 2001, aimed at oncology and autoimmune diseases [1][2] - AbbVie will have exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China [2] Financial Terms - IGI will receive an upfront payment of $700 million and is eligible for up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales [3] - The total potential financial benefit for IGI from this agreement could reach $1.925 billion [3] Product Details - ISB 2001 is a first-in-class trispecific T-cell engager targeting BCMA and CD38 on myeloma cells and CD3 on T cells, currently in Phase 1 for relapsed/refractory multiple myeloma [3] - Recent data from a study presented at the 2025 ASCO Annual Meeting showed a sustained overall response rate (ORR) of 79% and a complete/stringent complete response (CR/sCR) rate of 30% in heavily pretreated relapsed/refractory myeloma patients [4] Regulatory Status - The U.S. FDA granted ISB 2001 Orphan Drug Designation in July 2023 and Fast Track Designation for relapsed/refractory myeloma patients in May 2025 [5] Market Context - Other companies in the industry are also pursuing significant partnerships, such as AstraZeneca's reported talks with Summit Therapeutics for a $15 billion deal and BioNTech's agreement with Bristol Myers Squibb involving $1.5 billion upfront [5][6] - AbbVie’s stock price increased by 2.63% to $195.63 following the announcement [7]

Key Takeaways SMMT surged after reports of AstraZeneca exploring a $15 billion licensing deal for ivonescimab. The deal may include billions upfront, with milestone payments tied to Ivonescimab's progress. Ivonescimab showed superiority over Keytruda and Tevimbra in late-stage NSCLC trials.Shares of clinical-stage company Summit Therapeutics (SMMT) rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca (AZN) is in discussions with the company for a po ...

Corporate Strategy & Financial Position - BioNTech plans to strengthen its position through the acquisition of Biotheus, securing global control of BNT327 and expanding its immunotherapy capabilities[8] - The company reported a strong balance sheet with approximately €174 billion in total cash, cash equivalents, and security investments as of December 31, 2024[8] Oncology Pipeline & Clinical Development - BioNTech is advancing its oncology portfolio with 15 ongoing Phase 2 and Phase 3 trials[8] - BNT327 is being studied in 20+ clinical trials across multiple indications, with 3 global potentially registrational trials planned[36] - BNT327, in combination with chemotherapy, demonstrated a 738% objective response rate (ORR) in the ITT population in 1L TNBC[40] - Autogene cevumeran induced neoantigen-specific T cell responses in 71% of patients in a first-in-human study[65] mRNA Cancer Immunotherapy & Technology - BioNTech is prioritizing novel mRNA cancer immunotherapy, including FixVac and iNeST, targeting tumor-associated antigens and mutations[24] - The company has treated >450 patients and selected 18000 neoantigens using its iNeST platform[15] - BioNTech is leveraging AI to enhance its scientific capabilities and pioneer personalized immunotherapies[12] 2025 Priorities & Outlook - In 2025, BioNTech expects multiple randomized Phase 2 data readouts and will execute 7 ongoing Phase 2 trials and first novel combination trials[91] - The company aims to advance 3 global registration-enabling trials in potential fast-to-market indications in 2025[92]

Oncology Pipeline & Strategy - BioNTech has a multiplatform oncology portfolio with over 20 ongoing Phase 2 or 3 trials[7] - BNT327, a PD-L1/VEGF-A antibody, is a priority program with potential as a next-generation IO-backbone, with clinical activity observed across multiple indications in over 750 patients enrolled in 20+ clinical trials[7, 19, 20] - BNT327 combined with chemo in 1L TNBC showed an objective response rate (ORR) of 769% in PD-L1 negative, 563% in PD-L1 low, and 100% in PD-L1 high patients[25] - FixVac and iNeST are novel mRNA cancer immunotherapies targeting tumor-associated antigens and cancer mutations[7, 37] COVID-19 Vaccine & Financials - BioNTech anticipates maintaining a high market share in the U S, EU, and Japan for its COVID-19 vaccine[49] - The company expects total revenues between €1700 million and €2200 million for the financial year 2025[51] - R&D expenses for FY 2025 are projected to be between €2600 million and €2800 million[51] - SG&A expenses are estimated to be between €650 million and €750 million, with capital expenditure for operating activities between €250 million and €350 million[51] Financial Position - As of December 31, 2024, BioNTech's total cash plus security investments amounted to €174 billion, including €97619 million in cash and cash equivalents, €65362 million in current security investments, and €10611 million in non-current security investments[7, 8]

以下文章来源于投中网 ，作者蒲凡 投中网 . 投中网是领先的创新经济信息服务平台，拥有立体化传播矩阵，为创新经济人群提供深入、独到的智识和洞见，在私募股权投资行业和创新商业领域拥有权 威影响力。官网：www.chinaventure.com.cn 一笔交易直接赚麻了。 文 ｜ 蒲凡 来源｜ 投中网（ID：China-Venture） 封面来源｜ P exels 假如有这样一款神药：它可以有效治疗癌症，走出了一条与化疗的"杀敌一千、自损八百"截然不同的路线，一方面能够阻止恢复患者的T细胞功能，增强身 体对肿瘤的免疫反应，另一方面还能抑制肿瘤部位的血管生成，从而切断肿瘤的营养供应，双管齐下的抑制肿瘤的发展。与此同时，又因为这款神药可 以"双管齐下"，患者还能减少药物种类，降低药物相互作用的风险。 而你是一家制药公司的老板，你的技术顾问告诉你这款神药将成为下一代癌症治疗方案的"主角"，现在你有一个机会买下这款神药的研发权，你愿意出多少 钱？ 美国制药巨头百时美施贵宝的答案是，800亿。 日前，百时美施贵宝与德国生物技术公司BioNTech达成合作协议，获得联合开发和销售抗癌神药PD-L1/VEGF-A双特异性抗体B ...

Key Takeaways CVAC surged 40.8% in a month after a $1.25 billion acquisition agreement with BioNTech was announced. Each CVAC share is to convert to $5.46 in BNTX ADS, a 55% premium to its 3-month average price. Deal boosts BNTX's mRNA cancer pipeline and expands its infrastructure for global development efforts.Shares of CureVac N.V. (CVAC) have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE (BNTX) in an all-stock transaction last week. Per the ...

21世纪经济报道记者 季媛媛 韩利明 上海报道 密歇根湖的晚风轻拂，带来初夏的一丝燥热与期待。在全球肿瘤学界最重要的舞台——麦考密克会展中 心，ASCO（美国临床肿瘤学会）年会的穹顶下，一组数字正引发连锁反应：73项来自中国的研究登上 口头报告讲台。 "近年来，中国生物医药行业的投融资环境持续低迷，导致国内许多Biotech企业面临资金储备不足的问 题。在此背景下，对外授权（BD）交易成为企业重要的'造血'机制，通过这种方式，企业能够获得即 时的现金流，从而缓解生存压力。对于恒瑞医药、石药集团等头部企业，BD交易不仅是资金通道，更 是获取国际临床开发和商业化经验的'船票'。"该业内人说道。 本土创新究竟是待割的庄稼，还是"造血"工具？一场关于产业灵魂的争论正在发酵。 券商分析师们连夜修改估值模型。摩根士丹利将三家头部药企的目标价上调20%，理由直指"中国原创 研究首次在实体瘤领域实现对跨国药企的数量反超"。社交媒体上，"中国创新药崛起"的话题阅读量突 破2亿，配图是年轻科研人员在会场外举着印有公司logo的平板电脑合影。 繁荣背后也有B面。有跨国药企亚太区BD（商务拓展）负责人在行业闭门会上展示的PPT显示： ...

以下文章来源于投中网 ，作者蒲凡 投中网 . 投中网是领先的创新经济信息服务平台，拥有立体化传播矩阵，为创新经济人群提供深入、独到的智识 和洞见，在私募股权投资行业和创新商业领域拥有权威影响力。官网：www.chinaventure.com.cn 本文来自微信公众号： 投中网 （ID：China-Venture） ，作者：蒲凡，题图来自：AI生成 假如有这样一款神药：它可以有效治疗癌症，走出了一条与化疗的"杀敌一千、自损八百"截然不同的 路线，一方面能够阻止恢复患者的T细胞功能，增强身体对肿瘤的免疫反应，另一方面还能抑制肿瘤 部位的血管生成，从而切断肿瘤的营养供应，双管齐下的抑制肿瘤的发展。与此同时，又因为这款神 药可以"双管齐下"，患者还能减少药物种类，降低药物相互作用的风险。 而你是一家制药公司的老板，你的技术顾问告诉你这款神药将成为下一代癌症治疗方案的"主角"，现 在你有一个机会买下这款神药的研发权，你愿意出多少钱？ 美国制药巨头百时美施贵宝的答案是，800亿。 日前，百时美施贵宝与德国生物技术公司BioNTech达成合作协议，获得联合开发和销售抗癌神药 PD-L1/VEGF-A双特异性抗体BNT327 ...

将投中网设为"星标⭐"，第一时间收获最新推送 一笔交易直接赚麻了。 作者丨 蒲凡 来源丨 投中网 假如有这样一款神药：它可以有效治疗癌症，走出了一条与化疗的 " 杀敌一千、自损八百 " 截然不同的路线，一方面能够阻止恢复患者的 T 细胞功 能，增强身体对肿瘤的免疫反应，另一方面还能抑制肿瘤部位的血管生成，从而切断肿瘤的营养供应，双管齐下的抑制肿瘤的发展。与此同时，又因为 这款神药可以 " 双管齐下 " ，患者还能减少药物种类，降低药物相互作用的风险。 而你是一家制药公司的老板，你的技术顾问告诉你这款神药将成为下一代癌症治疗方案的 " 主角 " ，现在你有一个机会买下这款神药的研发权，你愿 意出多少钱？ 美国制药巨头百时美施贵宝的答案是， 800 亿。 什么叫赚麻了？这就叫赚麻了。 抗癌神药，中国造 这款神药名字里的 "PD-1/VEGF" ，指代的是 PD-1 和 VEGF 两个治疗靶点。 PD-1 是一种关键的免疫检查点蛋白，与 T 细胞、 B 细胞和 NK 细 胞等免疫细胞的表达程度息息相关。科学家们研究发现，当 PD-1 与其配体 PD-L1 和 PD-L2 结合时，会抑制 T 细胞的活性，帮助肿瘤细胞 ...

2025.06. 12 本文字数：2002，阅读时长大约4分钟 作者 | 第一财经 林志吟 在投资人与创新药企交流过程中，对外授权进展已成为绕不开的话题。 "创新药进入收获周期了，毕竟之前一直在投入研发，现在陆续取得积极的数据，实现对外授权交易 或上市销售。"一位创新药企人士对第一财经记者说。 在二级市场上，对于创新药企股价而言，对外授权交易似乎可以起到"点石成金"的效果。今年以 来，创新药概念股赚钱效应重现，有药企在对外授权预期笼罩下，市值重回千亿港元；有药企在达成 对外授权交易的当天，股价暴涨三成多。 59家港股18A生物科技企业中，今年以来股价累计涨幅翻倍的，数量达到25家。 火热的对外授权，火热的股价 近期，有两笔重磅对外授权交易，引发市场沸腾。 一笔是三生国健（688336.SH）及其关联公司沈阳三生，将双抗药物SSGJ-707海外独家开发、生 产、商业化权利授予辉瑞。三生国健与沈阳三生获得的首付款，可以达到12.5亿美元，这刷新国产 创新药出海首付款纪录。 另外一笔是百时美施贵宝与BioNTech达成共同开发和商业化BioNTech的双抗药物BNT327， BioNTech有望最高获得111亿美元 ...